Biodel to Report Second Quarter Fiscal Year 2010 Financial Results on May 6, 2010

DANBURY, Conn.--(BUSINESS WIRE)-- Biodel Inc. (Nasdaq: BIOD) will issue its second quarter fiscal year 2010 financial results on May 6, 2010. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.

May 6, 2010 schedule:

4:00 pm EDT:

  Q2 fiscal year 2010 results will be
distributed by Business Wire

4:15 pm EDT:

Conference call participants should dial:
+1 (877) 303-8028 (United States) or
+1 (760) 536-5167 (International)

4:30 pm EDT:

Conference call begins

Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at The audio webcast will be archived and available for replay through the website.

About Biodel

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. Biodel's new drug application for its most advanced product candidate, VIAject(R), has been accepted for review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act action date of October 30, 2010. Earlier stage product candidates include VIAtab(TM), a sublingual tablet formulation of insulin, a line of basal insulins and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at



The Trout Group LLC
Seth D. Lewis, +1-617-583-1308

KEYWORDS:   United States  North America  Connecticut

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical